CRISPR Therapeutics AG ( CRSP ) is trending Thursday, up more than 45% over the past month. Here’s a look at what’s driving the move.

What To Know: In late June, the company reported new early-stage data showing its experimental treatment CTX310 significantly lowered triglycerides and LDL cholesterol in patients, with no major safety issues. CRISPR Therapeutics ( CRSP ) said it plans to share full results in late 2025.

Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include:

Needham analyst Gil Blum reiterated a Buy rating on CRISPR and maintained a $81 price target.

Clear Street analyst Bill Maughan downgraded CRISPR from a Buy rating to a Hold rating and announced a $45 price target.

Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating on CRISPR and maintained a $105 price target.

JMP Securities analyst Silvan Tuerkcan reiterated a Market Outperform rating on CRISPR and maintained a $86 price target.

HC Wainwright & Co. analyst Mitchell Kapoor reiterated a Buy rating on CRISPR and maintained a $65 price target.

The consensus price target for CRISPR is $70.50, with the lowest price target sitting at $30 and the highest price target sitting at $120.

See Also: Forget Tech—Trump Just Made Defense The Hottest Trade On Wall Street

CRSP Price Action: At the time of writing, CRISPR shares are trading 1.84% lower at $58.97, according to data from Benzinga Pro.

Image via Shutterstock